POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the company will be publishing an abstract at ESMO Congress 2022, which takes place in Paris, France on September 9-13, 2022.

The abstract is titled “Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Mem-brane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH” (Abstract #1400P) and focuses on efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the Company’s phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of meta-static castration-resistant prostate cancer (mCRPC).

To read more please visit:

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Source: POINT